跳至主要内容
临床试验/NCT05746754
NCT05746754招募中不适用

Phase II Study of Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis

University of Aarhus4 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
50
试验地点
4
主要终点
CNS control

研究概览

简要总结

Leptomeningeal metastasis is a rare but serious complication to cancer, with a grave prognosis. No efficient treatment exists.

Recent data suggest that craniospinal radiotherapy lead to superior survival and CNS control compared to focal photon radiotherapy. We want to offer Danish patients the new treatment, but within a protocol, as this is new data with an new treatment principle

详细描述

Patients must be referred from Danish Departments of Oncology with radiotherapy service.

Patients with leptomeningeal metastasis from both solid and hematological cancers will be offered proton radiotherapy with 30 Gy in 10 fractions to the entire craniospinal axis. Patients will be followed with registration of side effects, neurology and MRI scans every 3 months until 1 year.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Metastasis to the leptomeningeal space (LM) surrounding the brain and/ or spinal cord
  • Metastasis verified by MRI or CSF cytology
  • Karnofsky >=60 (requiring some help, can take care of most personal requirements)
  • Adequate bone marrow function
  • Haemoglobin > 5 mmol/l
  • Absolute neutrophil count >1 10^9/l
  • Platelet count > 100 10^9/l
  • Patient consent
  • Female subjects must either be of non-reproductive potential ( ≥ 60 years old, or with no menses for >1 year without an alternative medical cause], OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a pregnancy test within 2 weeks prior to starting treatment.
  • Patient at reproductive potential must agree to practice an effective contraceptive method.

排除标准

  • • Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances (Yang)
  • Patient with multiple, serious major neurologic deficits per physician/investigator assessment including encephalopathy
  • Patient with extensive systemic disease and without reasonable systemic treatment options
  • Patient who is unable to undergo MRI brain and spine with gadolinium contrast
  • Pregnant or lactating women.

结局指标

主要结局

CNS control

时间窗: 6 months

local control

次要结局

  • CNS-PFS dependent on tumor site(1 year)
  • Symptomatology(1 year)
  • overall survival(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验